A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 370 participants.
Also called NCT01051011
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 370 participants
- Sponsor
- Registry
-
NCT01051011
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Hong Kong SAR China, Malaysia, Philippines, South Korea, Taiwan, Thailand
- Registry status
- Terminated
Technical summary
Registry record NCT01051011. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- insulin glargine
- Intervention (Drug)
- metformin
- Intervention (Drug)
- taspoglutide
- Intervention (Drug)
- taspoglutide
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01051011- Content hash
51490eadd5608452406d1a2bf5c0b577a76baf00d6cb9b29f1b295848c947fc3